News

Press Releases

FDA grants “Breakthrough Device Designation” to CorFlow Therapeutics to expedite clinical development and regulatory review of its CoFI (COF-fee) System
AAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the FDA has designated the company’s CoFI (Controlled Flow Infusion) System as a “Breakthrough Device” with a broad indication-for-use statement: “The CoFI System is indicated for diagnostic assessment of the coronary microcirculation immediately following PCI (“stenting”), and to be a platform for controlled infusion of therapeutic agents into the microcirculation with or without vessel occlusion.”
CorFlow Completes USD 9.7M in Seed Funding
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG today announced that the company has completed the 2nd close of its Seed+ financing round.